Prospects for 2015, page-2

Hi Joseph,
Yes with very good news possible for a FDA granting an interim review together with a full reimbursement decision in February all highly likely , SSH is in breakout mode , if we get both that could to a 50% partnership deal for the EU sale rights , I am a believer the fully implantable will be the game changer, as Dr Cowe says disruptive!
the angina and depression market is bigger than class 3/4 , SSH deserves a market cap over $2 billion with all this happening , cheers